Alternatives for the treatment of local advanced disease: Electrochemotherapy, limb perfusion, limb infusion, intralesional IL2.What is the role?

Dermatologic Therapy

Volumn 25, Issue 5, 2012, Pages 443-451

  Testori, Alessandro ^a   Intelisano, Antonio ^a   Verrecchia, Francesco ^a   Menicanti, Claudia ^a   Tosti, Giulio ^a   Grassi, Elisa ^a   Pari, Chiara ^a   Pennacchioli, Elisabetta ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

in transit metastasis; loco regional treatment; melanoma

Indexed keywords

ALPHA2B INTERFERON; IMIQUIMOD; INTERLEUKIN 2; ROSE BENGAL;

ADVANCED CANCER; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; ELECTROCHEMOTHERAPY; HUMAN; IMMUNOTHERAPY; LIMB INFUSION; LIMB PERFUSION; MELANOMA; METASTASIS; RISK FACTOR;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; ELECTROCHEMOTHERAPY; HUMANS; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MELANOMA; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RISK FACTORS; SKIN NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84867380438     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2012.01486.x     Document Type: Article

References (54)

1. Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following loco-regional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol 2008: 15 (5): 1476-1484.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009: 27 (36): 6199-6206.
3. Noorda EM, Vrouenraets BC, Nieweg OE, van, Geel BN, Eggermont AM, Kroon BB,. Isolated limb perfusion for unresectable melanoma of the extremities. Arch Surg 2004: 139: 1237-1242.
4. Gimbel MI, Delman KA, Zager JS,. Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control 2008: 15: 225-232.
5. Mir L,. Bases and rationale of the electrochemotherapy. Eur J Cancer Suppl. 2006: 4: 38-44.
6. Sadadcharam M, Soden DM, O'Sullivan GC,. Electrochemotherapy: an emerging cancer treatment. Int J Hyperthermia 2008: 24: 263-273.
7. Mir LM, Glass LF, Sersa G, et al. Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer 1998: 77: 2336-2342.
8. Testori A, Tosti G, Martinoli C, et al. Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther 2010: 23 (6): 651-661.
9. Byrne CM, Thompson JF,. Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors. Expert Rev Anticancer Ther 2006: 6: 671-678.
10. Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R,. Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 1996: 132: 1353-1357.
11. Heller R, Jaroszeski MJ, Reintgen DS, et al. Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin. Cancer 1998: 83: 148-157.
12. Quaglino P, Mortera C, Osella-Abate S, et al. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008: 15: 2215-2222.
13. Clark J, Grabs AJ, Parsons PG, et al. Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 1994: 4 (6): 365-370.
14. Aloia TA, Grubbs E, Onaitis M, et al. Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response. Arch Surg 2005: 140 (11): 1115-1120.
15. Eggermont AMM, de Wilt JHW, ten Hagen TLM,. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003: 4 (7): 429-437. Review.
16. Thompson JF, Gianoutsos MP,. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992: 16 (2): 227-233.
17. Alexander HR, Jr, Fraker DL, Bartlett DL, et al. Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters. J Clin Oncol 2010: 28 (1): 114-118.
18. Thompson JF, Hunt JA, Shannon KF, Kam PC,. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997: 132: 903-907.
19. Pace M, Gattai R, Mascitelli EM, Millanta L,. Results of isolated lower limb perfusion for loco-regional advanced/recurrent melanoma using borderline true hyperthermia plus additional bolus of melphalan. A critical analysis of homogeneous cases. J Surg Oncol 2011 Jun 30: 104: 718-723. doi: 10.1002/jso.21949.
20. Deroose JP, Eggermont AM, van, Geel AN, de, Wilt JH, Burger JW, Verhoef C,. 20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters. Ann Surg Oncol 2012 Aug 31: 19: 627-635.
21. Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol 2004: 11 (2): 173-177.
22. Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006: 24 (25): 4196-4201.
23. Rossi CR, Pasquali S, Mocellin S, et al. Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases. Ann Surg Oncol 2010: 17: 3000-3007.
24. Lejeune FJ, Eggermont AM,. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol 2007: 25 (11): 1449-1450; author reply 1450-1.
25. Grünhagen DJ, Brunstein F, Graveland WJ, van, Geel AN, de, Wilt JH, Eggermont AM,. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004: 240: 939-947; discussion 947-8.
26. Mian R, Henderson MA, Speakman D, Finkelde D, Ainslie J, McKenzie A,. Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg 2001: 44: 189-192.
27. Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008: 15: 2195-2205.
28. Barbour AP, Thomas J, Suffolk J, et al. Isolated limb infusion for malignant melanoma: predictors of response and outcome. Ann Surg Oncol 2009: 16: 3463-3472.
29. Lindnér P, Doubrovsky A, Kam PCA, Thompson JF,. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002: 9: 127-136.
30. Kroon HM, Moncrieff M, Kam PC, Thompson JF,. Outcomes of isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008: 15: 3003-3013.
31. Kroon HM, Lin DY, Kam PC, Thompson JF,. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced loco-regional melanoma. Ann Surg 2009: 246: 1008-1013.
32. Kroon HM, Moncrieff M, Kam PC, Thompson JF,. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin-D in melanoma patients. Ann Surg Oncol 2009: 16: 1184-1192.
33. Kroon HM, Lin DY, Kam PC, Thompson JF,. Efficacy of repeat isolated limb infusion with melphalan and actinomycin-D for recurrent melanoma. Cancer 2009: 115: 1932-1940.
34. Lindner P, Thompson JF, De Wilt JH, et al. Double isolated limb infusion with cytotoxic agents for recurrent and metastatic limb melanoma. Eur J Surg Oncol 2004: 30 (4): 433-439.
35. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009: 208: 706-715.
36. Beasley GM, McMahon N, Sanders G, et al. A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer 2009: 115: 4766-4774.
37. Goodnight JEJ, Morton DL,. The role of immunotherapy in the management of patients with malignant melanoma. World J Surg 1979: 3: 309-320.
38. Morton D, Eilber F, Malmgren R, Wood W,. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970: 68: 158-163.
39. Storm FK, Sparks FC, Morton DL,. Treatment for melanoma of the lower extremity with intralesional injection of bacilli Calmette Guerin and hyperthermic perfusion. Surg Gynecol Obstet 1979: 149: 17-21.
40. Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB,. Intralesional treatment of recurrent metastatic cutaneous melanoma: a randomized prospective study of intralesional bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer 1978: 41 (6): 2456-2463.
41. Faries M, Foshag L, Essner R, Morton D,. Intralesional BCG Immunotherapy in Metastatic Melanoma. San Francisco, CA, 2005.
42. Bauer R, Kopald KH, Lee J, et al. Long-term results of intralesional BCG for locally advanced recurrent melanoma. Proc Am Soc Clin Oncol 1990: 9: 276.
43. Sparks F, Silverstein M, Hunt J, Haskell C, Pilch Y, Morton D,. Complications of BCG immunotherapy in patients with cancer. N Engl J Med 1973: 289: 827-830.
44. Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer 2003: 89 (9): 1620-1626.
45. Den Otter W, Jacobs JJ, Battermann JJ, et al. Local therapy of cancer with free IL-2. Cancer Immunol Immunother 2008: 57 (7): 931-950.
46. Von Wussow P, Block B, Hartmann F, Deicher H,. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988: 61 (6): 1071-1074.
47. Ridolfi L, Ridolfi R, Ascari-Raccagni A, et al. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients. J Eur Acad Dermatol Venereol 2001: 15 (3): 218-223.
48. Si Z, Hersey P, Coates A,. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res 1996: 6 (3): 247-255.
49. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S,. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 2010: 17 (3): 718-730.
50. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD,. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 2007: 156 (2): 337-345.
51. Berman B, Poochareon VN, Villa AM,. Novel dermatologic uses of the immune response modifier imiquimod 5% cream. Skin Therapy Lett 2002: 7 (9): 1-6.
52. Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S,. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 2000: 89 (12): 2646-2654.
53. Molenkamp BG, Sluijter BJ, van, Leeuwen PA, et al. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 2008: 14 (14): 4532-4542.
54. Thompson JF, Hersey P, Wachter E,. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res 2008: 18: 405-411.